Jci_page_head_homepage_01 Jci_page_head_homepage_02
Christine Varela, Jérôme Alexandre Denis, Jérôme Polentes, Maxime Feyeux, Sophie Aubert, Benoite Champon, Geneviève Piétu, Marc Peschanski, Nathalie Lefort
Published in Volume 122, Issue 2
J Clin Invest. 2012; 122(2):569–574 doi:10.1172/JCI46268
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Jci46268
Figure 3
Differentiation potential in vitro and in vivo.

(AF) In vitro neuronal differentiation potential. 3 weeks after growth factor withdrawal, normal VUB01 passage 18 NSCs (A), normal VUB05-HD passage 15 NSCs (B), and mutant VUB05-HD (batch b) passage 61 NSCs (C) differentiated in vitro into TUBB3-positive neurons. (D) Number of neurons generated with normal VUB01 and VUB05 and mutant VUB05-HD (batch a and b) NSC lines, determined using the neuronal nuclear marker HuCD. Samples of normal and mutant cell lines were differentiated in at least 3 independent experiments. The proportion of HuCD-positive cells (± SEM) was determined in at least 1,000 cells per sample in randomly picked fields. NSC lines bearing 1q duplication failed to differentiate into neurons, except mutant VUB05-HD (batch b). (E and F) 2 weeks after growth factor withdrawal, normal VUB01 passage 18 NSCs (E) differentiated in vitro into neurons, whereas mutant VUB01 passage 71 NSCs (F) failed to give rise to neurons and died. (G and H) In vivo differentiation potential. 7 weeks after grafting, human nestin- and MAP2-positive cells were observed with rat brain transplants of normal VUB01 passage 21 NSCs (G), but not with mutant VUB01 passage 74 NSCs (H). Scale bars: 50 μm.